The PIM kinase inhibitor TP-3654 demonstrates efficacy in a murine model of myelofibrosis

被引：2
|
作者：
Dutta, Avik [1 ]
Nath, Dipmoy [1 ]
Yang, Yue [1 ]
Mohi, Golam [1 ]
机构：
[1] Univ Virginia, Charlottesville, VA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1874
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1874
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models
    Nath, Dipmoy
    Dutta, Avik
    Yang, Yue
    Whatcott, Clifford
    Warner, Steven L.
    Mohi, Golam
    BLOOD, 2018, 132
  • [2] Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
    Dutta, Avik
    Nath, Dipmoy
    Yang, Yue
    Le, Bao T.
    Rahman, Mohammad Ferdous-Ur
    Faughnan, Patrick
    Wang, Zhenjia
    Stuver, Matthew
    He, Rongquan
    Tan, Wuwei
    Hutchison, Robert E.
    Foulks, Jason M.
    Warner, Steven L.
    Zang, Chongzhi
    Mohi, Golam
    LEUKEMIA, 2022, 36 (03) : 746 - 759
  • [3] Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models
    Avik Dutta
    Dipmoy Nath
    Yue Yang
    Bao T. Le
    Mohammad Ferdous-Ur Rahman
    Patrick Faughnan
    Zhenjia Wang
    Matthew Stuver
    Rongquan He
    Wuwei Tan
    Robert E. Hutchison
    Jason M. Foulks
    Steven L. Warner
    Chongzhi Zang
    Golam Mohi
    Leukemia, 2022, 36 : 746 - 759
  • [4] Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
    El Chaer, Firas
    Yuda, Junichiro
    Mccloskey, James
    Rein, Lindsay
    Brown, Randy
    Green, Steven
    Pu, Jeffrey
    Shirane, Shuichi
    Shimoda, Kazuya
    Ichii, Michiko
    Scandura, Joseph
    Kabir, Sujan
    Foulks, Jason M.
    Mei, Jian
    Yang, Huyuan
    Wade, Mark
    Stapinski, Carl
    Lebedinsky, Claudia
    Rampal, Raajit K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1427 - S1427
  • [5] Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
    Rein, Lindsay A. M.
    El Chaer, Firas
    Yuda, Junichiro
    Shimoda, Kazuya
    Rampal, Raajit
    Scandura, Joseph M.
    Takami, Akiyoshi
    Mccloskey, James
    Ichii, Michiko
    Shirane, Shuichi
    Iurlo, Alessandra
    Bose, Prithviraj
    Lucchesi, Alessandro
    Benevolo, Giulia
    Amanam, Idoroenyi
    Vachhani, Pankit
    Tantravahi, Srinivas K.
    Rotta, Marcello
    Onishi, Yasushi
    Kiladjian, Jean-Jacques
    Rinaldi, Ciro
    Granacher, Nikki
    Bradley, Terrence
    Patel, Anand Ashwin
    Loschi, Michael
    Alimam, Samah
    Cheung, Stanley
    Ribrag, Vincent
    Kabir, Sujan
    Seki, Masataka
    Pharmd, Karen Ansaldo
    Guffanti, Guia
    Lee, Jinny
    Warner, Steven L.
    Foulks, Jason M.
    Mesa, Ruben
    BLOOD, 2024, 144 : 3180 - 3181
  • [6] A Phase I Study of TP-3654, an Oral PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis (MF)
    Lebedinsky, Claudia
    Kabir, Sujan
    Warner, Steven
    Mohi, Golam
    Yang, Huyuan
    Mei, Jian
    Braendle, Edgar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S355 - S356
  • [7] A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis
    Lebedinsky, Claudia
    Anthony, Stephen P.
    Mohi, Golam
    Yang, Huyuan
    Mei, Jian
    Braendle, Edgar
    BLOOD, 2020, 136
  • [8] A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis
    Mascarenhas, John O.
    Rampal, Raajit
    El Chaer, Firas
    Gupta, Vikas
    Shimoda, Kazuya
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Bose, Prithviraj
    Scandura, Joseph M.
    Mesa, Ruben
    Rein, Lindsay A. M.
    Yuda, Junichiro
    Ross, David M.
    Devos, Timothy
    Talpaz, Moshe
    Hoffman, Ronald
    Kabir, Sujan
    Li, Zhonggai
    Foulks, Jason M.
    Ansaldo, Karen
    Seki, Masataka
    Peddagali, Vishnu
    Shah, Jatin
    Harrison, Claire
    BLOOD, 2024, 144 : 6629 - 6631
  • [9] Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy
    El Chaer, Firas
    McCloskey, James
    Rein, Lindsay A. M.
    Brown, Randy A.
    Green, Steven D.
    Pu, Jeffrey J.
    Shirane, Shuichi
    Shimoda, Kazuya
    Ichii, Michiko
    Yuda, Junichiro
    Scandura, Joseph
    Kabir, Sujan
    Foulks, Jason M.
    Mei, Jian
    Yang, Huyuan
    Wade, Mark
    Stapinski, Carl
    Lebedinsky, Claudia
    Rampal, Raajit K.
    BLOOD, 2022, 140
  • [10] Pharmacodynamic biomarkers for Pim inhibition with TP-3654 in patients with solid tumors.
    Allred, Curtis A.
    Matsumura, Yuta
    Tyagi, Ethika
    Wade, Mark
    Whatcott, Clifford
    Foulks, Jason
    Siddiqui, Adam
    Bearss, David J.
    Warner, Steven L.
    CANCER RESEARCH, 2021, 81 (13)
12345